AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05272280 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: External oblique intercostal (EOI) block
Description: A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation at the sixth intercostal space in the anterior midaxillary line. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the external oblique muscle. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
Study NCT05272280 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block (ESPB)
Description: A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of Local Anesthetic mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
Study NCT05542199 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral weight loss program
Description: Enrollment in behavioral weight loss intervention for 12 months modeled on the Diabetes Prevention Program.
Study NCT05542199 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral weight loss program
Description: Enrollment in behavioral weight loss intervention for 12 months modeled on the Diabetes Prevention Program.
Study NCT05978778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wii sports game
Description: wii sports is a collection five sports game stimulation,which have been designed to demonstrate the motion sensing capabilities of wii remote
Study NCT05978778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pre-hand writing skills
Description: pre-hand writing skills
Study NCT05978778 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pre-hand writing skills
Description: pre-hand writing skills
Study NCT06692933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 75 mg oral clopidogrel
Study NCT06692270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg Q3W, D1 ; 2 cycles
Study NCT06692647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4318
Description: Oral administration
Study NCT06692647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Oral administration
Study NCT06692816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: As a therapeutic exercise program, it was planned to apply joint range of motion, walking, balance, coordination, cycling, isometric and isotonic strengthening exercises by a trained physiotherapist with at least 5 years of experience and that the patients would do these exercises three times a day, in 3 sets, with 10 repetitions.
Study NCT06692816 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Rehabilitation
Description: As a therapeutic exercise program, it was planned to apply joint range of motion, walking, balance, coordination, cycling, isometric and isotonic strengthening exercises by a trained physiotherapist with at least 5 years of experience and that the patients would do these exercises three times a day, in 3 sets, with 10 repetitions.
Study NCT06692842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONEMO App
Description: The CONEMO application has three protocol, aimed to improived symptoms of depression, insomnia and anxiety. It is based on cognitive behavioral therapy (CBT) and contextual behavioral therapy (activation behavioral theraphy, mindfulness) and adapted considering broader contexts of mental health care, which involves a low-intensity intervention administered without any or minimal professional guidance and widely accessible. In a brief and structured format, CONEMO involves offering the intervention through texts, audios and videos. Based on the principles of CBT and contextual thrapies, CONEMO is organized into structured sessions that promote psychoeducation and teach basic behavioral skills, often through interactive exercises. Each journey was developed based on scientific evidences. The CONEMO journeys comprise seven weekly modules.
Study NCT05543889 — intervention group
Intervention type: OTHER
Intervention: Educational package
Description: Online learning package that will discuss the van Herick technique, grading, accuracy and information and discusses the current guidelines for primary angle closure suspect referral.
Study NCT06734325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Oral Health Intervention
Description: 46 messages delivered over a 3-month period (12 weeks) via WhatsApp
Study NCT06737627 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT06748014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aescin in Horse Chestnut
Description: Patient will recived MPFF 3000 mg for 7 day then 1000 mg for 2 month + Aescin 60 mg for 2 month
Study NCT06748014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MPFF
Description: MPFF 3000 mg 7 day then 1000 mg 2 months
Study NCT06748014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MPFF
Description: MPFF 3000 mg 7 day then 1000 mg 2 months
Study NCT06747013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point Ablation Catheter
Description: a point ablation catheter using a pulse field energy
Study NCT06747728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients were enrolled and given bevacizumab on days 1 and 15, administered by intravenous infusion at 5 mg/kg.
Study NCT06746870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM2510
Description: Cohort1:~Phase I #: 10 mg/kg or 20 mg/kg, Q3W, intravenous infusion Phase II \&: 20 mg/kg, Q3W, intravenous infusion~Cohort2:~Phase I #: 10 mg/kg or 20 mg/kg, Q2W, intravenous infusion Phase II \&: 20 mg/kg, Q2W, intravenous infusion
Study NCT06746870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (pemetrexed + cisplatin/carboplatin)
Description: Non-squamous non-small cell lung cancer (NQ-NSCLC): Pemetrexed 500 mg/m2 in combination with carboplatin (AUC 5-6) or cisplatin (75 mg/m2), intravenous infusion, Q3W, for 4 cycles, followed by maintenance treatment with pemetrexed
Study NCT06746870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (paclitaxel + cisplatin/carboplatin)
Description: Squamous non-small cell lung cancer (SQ-NSCLC): Paclitaxel 175 mg/m2 + carboplatin (AUC 5-6) or cisplatin (75 mg/m2), intravenous infusion, Q3W, for 4 cycles.
Study NCT06746870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy(Nab-paclitaxel)
Description: Nab-paclitaxel, 100 mg/m2, 4 weeks as a cycle, administered on D1, 8, and 15 of each cycle.
Study NCT06746727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy for Social Health, Achievement, and Relationship Effectiveness (ACT-SHARE)
Description: This single-arm intervention will pilot a new, manualized intervention adapted from existing interventions using Acceptance and Commitment Therapy (ACT) to address alcohol use, PTSD, social functioning, and IPV use. ACT for Social Health, Achievement, and Relationship Effectiveness (ACT-SHARE) aims to assist Veterans in developing skills central to psychological flexibility (e.g., acceptance, mindfulness, commitment to values-based action) to improve their relationship functioning and decrease IPV use in the presence of PTSD symptoms (e.g., anger, irritability, detachment from others) and alcohol use issues (e.g., cravings, triggers, disconnection from valued roles).
Study NCT06747182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile phone-based intervention
Description: Participants in intervention group will receive a 12-week mobile phone-based intervention with follow-up at week 26.
Study NCT06746844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViewMind Atlas™
Description: The intervention involves the use of ViewMind Atlas™, a novel digital tool for cognitive assessment, and traditional cognitive tests. The ViewMind Atlas™ device evaluates cognitive performance through eye-tracking technology and advanced analytics, providing objective measurements of cognitive function. Traditional cognitive tests are used as the standard comparator to validate the device's diagnostic performance
Study NCT06745999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ameluz 10% Topical Gel
Description: Paired with device intervention of red light PDT
Study NCT06745999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red Light PDT
Description: Paired with drug intervention of Ameluz 10% topical gel
Study NCT06745999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Liquid Nitrogen
Study NCT06746649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined training
Description: 12-week long time specific combined training 2 times a week
Study NCT06747832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iNK cells
Description: Intravenous infusion of iNK cells is given to the subject, 5\*108 to 1\*109 cells/dose, three doses per week, a total of 6 doses. And then 1\*109 cells/dose, one doses every 4 weeks , a total of 5 doses.
Study NCT06746532 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intranasal breast milk
Description: Own-mother's fresh breast milk (within 4 hours of having been expressed), is administered intranasally to neonates with hypoxic-ischemic encephalopathy receiving therapeutic hypothermia, starting from the first day of life and continuing for 28 days.~Dose: 2 times daily, 0.4 ml in each nostril.
Study NCT04765215 — intervention group
Intervention type: BIOLOGICAL
Intervention: CoronoVAC
Description: SARS-CoV-2 IgM and IgG will be measured from blood samples between 3-6 weeks after the 2nd dose of vaccination
Study NCT05386576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: During Induction I, for patients on Dose Level 1, venetoclax will be administered at a dose of 100mg on day 5, 200mg on day 6 and 400mg on days 7-28. For patients on Dose Level 01, venetoclax will be administered at a dose of 100mg on day 5 and 200mg on days 6-28.~During Induction II, venetoclax will be administered at either 400mg daily (Dose Level 1) or 200mg daily (Dose Level -1) from days 1-14 and 29-42.
Study NCT04743076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Description: Endovascular treatment
Study NCT06341374 — intervention group
Intervention type: BIOLOGICAL
Intervention: Influvac Tetra
Description: All participants will take influenza vaccine (Influvac Tetra, Abbott Biologicals, IL, USA) and the trained immune response will be evaluated.
Study NCT04743076 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment
Description: Standard medical treatment
Study NCT04743076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical treatment
Description: Standard medical treatment
Study NCT06025305 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intravascular imaging test
Description: Coronary artery disease patients first underwent CCTA and then intravascular imaging test within 3 months
Study NCT06013852 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: processing the radiography with the Boneview software
Description: all X-Rays will be analysed with and without the software
Study NCT06357715 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: slumpposition
Description: neurodynamic sliding mobilisation in the slump position
Study NCT04893135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pratice physical activity
Description: treadmill walking : walk at a speed of 2.7 km.h-1 in 3 stages of 3 mins with an incline of 0%, 5% and 10%
Study NCT06049108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3871801
Description: Administered orally
Study NCT06244108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational therapy home program
Description: After evaluating the children, an occupational therapy home intervention program will be developed for each child. The program will be monitored through telephone and computer interviews, as well as video, photo, and audio recordings. The interventions in this study were selected based on successful occupational therapy home programs for children with disabilities. The program consists of five steps.~Step 1 is to establish collaborative relationships with parents. Step 2 is to determine the most appropriate goals for the child and their family. Step 3 involves selecting the most suitable therapeutic activities to achieve these goals. Step 4 is to educate and support parents in performing these therapeutic activities. Finally, Step 5 involves measuring the results and providing feedback.
Study NCT04945694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral pecto-intercostal fascial block
Description: - PATIENT IN SUPINE POSITION, SKIN WILL BE DISINFECTED, A HIGH-FREQUENCY LINEAR PROBE WILL BE PLACED PARALLEL TO LONGITUDINAL AXIS OF STERNUM ON LATERAL BORDER AND SCANNED LATERALLY TO IDENTIFY 4TH AND 5TH COSTAL CARTILAGE. THE PECTORALIS MAJOR MUSCLE (PMM), INTERNAL INTERCOSTAL MUSCLE (IIM), TRANSVERSUS THORACIS MUSCLE (TTM), RIBS, AND PLEURA WILL BE IDENTIFIED. COLOR DOPPLER ULTRASONOGRAPHY WILL BE USED TO DETERMINE PERFORATING BRANCHES OF INTERNAL THORACIC ARTERY, WHICH TRAVEL ANTERIORLY THROUGH THE ANTERIOR CHEST WALL, PIERCING THE INTERCOSTAL MUSCLE AND PMM. A 22G NEEDLE WILL BE INSERTED IN PLANE WITH PROBE, IN CAUDAL-TO-CRANIAL DIRECTION UNTIL THE TIP IS POSITIONED IN INTER- FASCIAL PLANE BETWEEN THE PMM AND IIM. NORMAL SALINE WILL BE USED TO DETERMINE CORRECT PLACEMENT OF NEEDLE TIP IN INTER-FASCIAL PLANE, AS SHOWN BY SEPARATION OF FASCIAL LAYERS THEN LOCAL ANESTHETIC WILL BE INJECTED
Study NCT04945694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous fentanyl
Description: In this group, patients will receive only incremental doses of intravenous fentanyl
Study NCT04945694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Propofol anesthesia
Study NCT04945694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol anesthesia
Study NCT04945694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane anesthesia
Study NCT04945694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane anesthesia
Study NCT04945694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atracurium
Description: Intravenous atracurium
Study NCT04945694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atracurium
Description: Intravenous atracurium
Study NCT04945694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: ultrasound-guided block
Study NCT06556212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-time feedback using smart swim goggles
Description: Smart swim goggles (Form Athletica Inc.) with activity metrics (such as heart rate, swimming pace, and workout instructions) displayed in real-time during a swimming activity.
Study NCT04940936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Patient Decision Aid
Description: The Patient Decision Aid informs about the pros and cons of each option
Study NCT04633824 — intervention group
Intervention type: OTHER
Intervention: Retrospective Electronic Medical Record Review
Description: Patients will be assessed retrospectively for evidence of successful or failed epidural extension in the setting of need for cesarean section
Study NCT05401968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Osteoporosis patient education
Description: During osteoporosis patient education the participants get knowledge about e.g. osteoporosis, medication, and diet, and they participate in physical exercises. Though, differences between municipalities exist. The participants meet in groups and face-to-face.
Study NCT06357715 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: slumpposition
Description: neurodynamic sliding mobilisation in the slump position
Study NCT06357715 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no slump position
Description: placebo
Study NCT06357715 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no slump position
Description: placebo
Study NCT05852340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritlecitinib
Description: ritlecitinib 1 x 30 mg intact BiC (Treatment Arms A, E)~ritlecitinib 1 x 30 mg intact BiC sprinkled on soft foods (Treatment Arms B, C, D)
Study NCT05278104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zentiva®
Description: Zentiva®
Study NCT05278104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06276465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darolutamide 300 mg
Description: 2 tablets of 300 mg twice daily (=1200 mg/day) up to 5 years from randomisation
Study NCT06276465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide 300 mg
Description: 2 tablets of 300 mg twice daily (=1200 mg/day) up to 5 years from randomisation
Study NCT06276465 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: Over one week,30 Gy in 3 fractions of 10 Gy
Study NCT06276465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen deprivation therapy
Description: Continuous ADT during the study course. The choice of ADT is left to the discretion of the investigator.
Study NCT06276465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Description: Continuous ADT during the study course. The choice of ADT is left to the discretion of the investigator.
Study NCT05800574 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy (5 days for 7 weeks)
Description: Mon-Fri (5 days for 7 weeks), total 35 fractions over 35 treatment days of radiation therapy (RT)
Study NCT05800574 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy (5 days for 6 weeks)
Description: Mon-Fri (5 days for 6 weeks), total 35 fractions over 30 treatment days of RT (two doses 6 hours apart except for the last 6th Friday of the 6 weeks )
Study NCT05800574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin, 40mg/m2 (weekly for 7 weeks)
Study NCT05667142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN1101
Description: XEN1101 capsules
Study NCT05667142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT05925803 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Anifrolumab (blinded)
Description: Anifrolumab treatment delivered subcutaneously, once weekly for 52 weeks
Study NCT05925803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (blinded)
Description: matched placebo delivered subcutaneously, once weekly for 52 weeks
Study NCT05925803 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Anifrolumab (unblinded, open label)
Description: At Week 52, all patients will receive Anifrolumab subcutaneously once weekly for 52 weeks
Study NCT04702893 — intervention group
Intervention type: DRUG
Intervention: Nintedanib
Description: Nintedanib
Study NCT05603104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: See arm description
Study NCT05193383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginal exposure
Description: Session 1 (Day 1): Participants receive repeated exposure to mental imagery of fear-provoking stimuli (spiders) and neutral stimuli (leaves) while undergoing brain imaging med fMRI.
Study NCT05193383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: Session 2 (Ca one week): Participants receive both imaginal and in vivo exposure to fear-provoking stimuli and neutral stimuli (both arms are exposed to both video clips (in vivo exposure) and mental imagery (imaginal exposure). Session 2 is conducted in the laboratory, i.e., no brain imaging.
Study NCT05616221 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AP-PA02
Description: Bacteriophage administered via inhalation
Study NCT05193383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Approach-avoidance conflict
Description: Session 2 (Ca one week): Spider fear is probed by an approach-avoidance conflict task. Participants can receive varying small rewards for watching pictures of spiders, or avoid the spider pictures at the cost of not receiving a reward (neutral pictures are shown instead).
Study NCT05193383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In vivo exposure
Description: Session 1 (Day 1): in vivo exposure. Participants receive repeated exposure to film clips of fear-provoking stimuli (spiders) and neutral stimuli (leaves) while undergoing brain imaging med fMRI.